Affordable Access

A comparison of a new graduated estrogen formulation with three constant-dosed oral contraceptives.

Authors
  • Appel, T B1
  • Kambi, A A
  • Birdsall, C
  • Christenson, D A
  • Clark, D O
  • DeKoning, J R
  • Dreisbach, L A
  • Frost, J F
  • Gustin, A E
  • Halikis, M
  • 1 Boulder Medical Center, CO.
Type
Published Article
Journal
Contraception
Publisher
Elsevier
Publication Date
Jun 01, 1987
Volume
35
Issue
6
Pages
523–532
Identifiers
PMID: 3311619
Source
Medline
Keywords
License
Unknown

Abstract

Four-hundred-twenty-six women, aged 18 to 36, completed a four-cycle comparative, randomized, single-blind (observer blind), multicenter study of a new graduated estrogen formulation with three constant-dosed combination oral contraceptives containing the same synthetic steroid compounds. The products studied were Loestrin 1/20, Loestrin 1.5/30, Norlestrin 1/50, and a new graduated estrogen product, Estrostep. A total of 1,850 cycles were completed and analyzed for efficacy, side effects, metabolic changes, and cycle control. Four pregnancies occurred during the course of the study. None of the pregnancies occurred in the group receiving Estrostep. The new formulation produced the lowest rate of breakthrough bleeding (BTB) compared with the other three products. All four combination oral contraceptives resulted in an increase in high-density lipoprotein cholesterol (HDL-C). The levels of HDL-C were greatest with Estrostep.

Report this publication

Statistics

Seen <100 times